Biological significance of allele specific loss of the p53 gene in breast carcinomas

Breast Cancer Research and Treatment

Volumn 118, Issue 1, 2009, Pages 15-20

  Wegman, Pia P ^a,b   Marcus, Nashwan J ^b   Malakkaran, Breezy Paul ^a   Wingren, Sten ^a  

^a ÖREBRO UNIVERSITY   (Sweden)

^b LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Breast cancer; Codon 72; Loss of heterozygosity; P53; P53 Mutations

Indexed keywords

ARGININE; PROTEIN P53;

ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE S PHASE; CODON; CONTROLLED STUDY; FEMALE; GENE LOSS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; TUMOR SUPPRESSOR GENE;

AGE OF ONSET; AGED; AGED, 80 AND OVER; ALLELES; BREAST NEOPLASMS; CARCINOMA; CODON; ESTROGENS; FEMALE; GENES, P53; HUMANS; KAPLAN-MEIERS ESTIMATE; LOSS OF HETEROZYGOSITY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; POLYMORPHISM, SINGLE NUCLEOTIDE; POSTMENOPAUSE; PROGNOSIS; RECEPTORS, ESTROGEN; S PHASE; SWEDEN;

EID: 70349925975     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-008-0212-1     Document Type: Article

References (33)

1. M Hollstein D Sidrowsky B Vogelstein C Harris 1991 p53 Mutations in human cancers Science 253 46 53 10.1126/science.1905840
2. AJ Giaccia MB Kastan 1998 The complexity of p53 modulation: emerging patterns from divergent signals Genes Dev 12 2973 2983 10.1101/gad.12.19.2973 1:CAS:528:DyaK1cXmslejtbs%3D 9765199
3. M Thomas A Kalita S Labrecque D Pim L Banks G Matlashewski 1999 Two polymorphic variants of wild-type p53 differ biochemical and biologically Mol Cell Biol 19 1092 1100 1:CAS:528:DyaK1MXhtVKhsL0%3D 9891044
4. P Dumont JI Leu AC Della DL Pietra G Murphy 2003 The codon72 polymorphic variants of p53 have markedly different apoptotic potential Nat Genet 33 357 365 10.1038/ng1093 1:CAS:528:DC%2BD3sXhsV2ktbc%3D 12567188 (Pubitemid 36278852)
5. A Sullivan N Syed M Gasco D Bergmaschi G Trigiante M Attard I Hiller PJ Farrel P Smith X Lu T Crook 2004 Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo Oncogene 23 3328 3337 10.1038/sj.onc.1207428 1:CAS:528:DC%2BD2cXjtlChu78%3D 15077186 (Pubitemid 38669822)
6. D Pim L Banks 2004 p53 Polymorphic variants at codon72 exerts different effects on cell cycle progression Int J Cancer 108 196 199 10.1002/ijc.11548 1:CAS:528:DC%2BD3sXhtVWgu7zI 14639602 (Pubitemid 37541770)
7. D Bergamaschi Y Samuels A Sullivan M Zvelebil H Breyssens A Bisso G Del Sar N Syed P Smith M Gasco T Crook X Lu 2006 iASPP preferentially binds proline-rich region and modulate apoptotic function of codon 72-polymorphic p53 Nat Genet 38 1133 1141 10.1038/ng1879 1:CAS:528:DC%2BD28XhtVSns73K 16964264 (Pubitemid 44470358)
8. J Tommiska H Eerola M Heinonen L Salonen M Kaare J Tallila A Ristimaki KV Smitten K Aittomaki P Heikkila C Blomqvist H Nevanlinna 2005 Breast cancer patients with p53 Pro 72 homozygous genotype have a poorer survival Clin Cancer Res 11 5098 5103 10.1158/1078-0432.CCR-05-0173 1:CAS:528:DC%2BD2MXmt12qtLk%3D 16033823 (Pubitemid 41003693)
9. EN Papadakis DN Dokianakis DA Spandidos 2000 p53 Codon72 polymorphism as a risk factor in the development of breast cancer Mol Cell Biol Res Commun 3 389 392 10.1006/mcbr.2000.0241 1:CAS:528:DC%2BD3cXotlGiuro%3D 11032762 (Pubitemid 30803131)
10. N Byuru H Tigli N Dalay 2003 p53 Codon72 polymorphism in breast cancer Oncol Rep 10 711 714
11. XE Huang N Hamajima N Katsuda K Matsuo K Hirose M Mizutani H Iwata S Miura S Tokudome K Tajima 2003 Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphism with the risk of Japanese breast cancer Breast cancer 10 307 311 10.1007/BF02967650 14634508
12. C Noma Y Miyoshi T Taguchi Y Tamaki S Noguchi 2004 Association of p53 codon72 polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women Cancer Lett 210 197 203 10.1016/j.canlet.2004.03.031 1:CAS:528:DC%2BD2cXks1Wrsb4%3D 15183535 (Pubitemid 38748690)
13. I Mabrouk S Baccouche R Abed R Mokdad-Gargouri A Mosbah S Said J Daoud M Frikha R Jlidi A Gargouri 2003 No evidence of correlation between p53 codon72 polymorphism and risk of bladder or breast carcinoma in Tunisian patients Ann N Y Acad Sci 1010 764 770 10.1196/annals.1299.137 1:CAS:528:DC%2BD2cXisFeqtrY%3D 15033824 (Pubitemid 38265078)
14. M Bonafe C Ceccarelli F Farabegoli D Santini M Taffurelli C Barbi E Marzi C Trapassi G Storci F Oliveri C Franceschi 2003 Retention of the codon72 Arginine allele is associated with a reduction of disease-free and overall survival in Arginine/Proline heterozygous breast cancer patients Clin Cancer Res 9 4860 4864 1:CAS:528:DC%2BD3sXosVGjt7s%3D 14581358
15. R Schneider-Stock C Boltz B Peters R Szibor O Landt F Meyer A Roessner 2004 Selective loss of codon72 Proline p53 and frequent mutational inactivation of retained Arginine allel in colorectal cancer Neoplasia 6 529 535 10.1593/neo.04178 1:CAS:528:DC%2BD2cXhtVShurfI 15548361 (Pubitemid 39411089)
16. S Mitra S Banerjee C Misra RK Singh A Roy A Sengupta CK Panda S Roychoudhury 2007 Interplay between human papilloma virus infection and p53 gene alterations in head and neck squamous cell carcinoma of an Indian population J Clin Pathol 60 1040 1047 10.1136/jcp.2005.034835 1:CAS:528:DC%2BD2sXhtFGgt73E 17079356 (Pubitemid 47441939)
17. T Toyama Z Zhang M Nishio M Hamaguchi N Kondo H Iwase H Iwata S Takahashi H Yamashita Y Fujii 2007 Association of TP53 codon 72 polymorphism and the outcome of adjuvant therapy in breast cancer patients Breast Cancer Res 9 R34 10.1186/bcr1682 17537232 (Pubitemid 350215173)
18. M Kyndi J Alsner LL Hansen F Sorensen J Overgaard 2006 LOH rather than genotypes of TP53 codon 72 is associated with disease-free survival in primary breast cancer Acta Oncol 45 602 609 10.1080/02841860600660811 1:CAS:528:DC%2BD28XhtVWrtbzM 16864176 (Pubitemid 44167213)
19. P Wegman S Elingarami J Carstensen O Stål B Nordenskjöld S Wingren 2007 Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer Breast Cancer Res 9 1 R7 10.1186/bcr1640 17244352 (Pubitemid 350215154)
20. LA Brooks JA Tidy B Gusterson L Hiller J O'Nions M Gasco MC Marin PJ Farrel W Kaelin T Crook 2000 Preferential retention of codon72 Arginine p53 in squamous cell carcinoma of the vulva occurs in cancers positive and negative for human papillomavirus Cancer Res 60 6875 6877 1:CAS:528:DC%2BD3MXjsVKqtg%3D%3D 11156383
21. RE Buller A Sood C Fullenkamp J Sorosky K Powills B Anderson 1997 The influence of the p53 codon72 polymorphism on ovarian carcinogenesis and prognosis Cancer Gene Ther 4 239 245 1:CAS:528:DyaK2sXkvFemtrc%3D 9253509
22. ED Papadakis N Soulitiz DA Spandidos 2002 Association of p53 codon72 Polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes Br J Cancer 87 1013 1018 10.1038/sj.bjc.6600595 1:CAS:528:DC%2BD38Xoslaksrk%3D 12434294 (Pubitemid 35305655)
23. H Kawaguchi S Ohno K Araki M Miyazaki H Saeki M Watanabe S Tanaka K Sugimachi 2000 p53 Polymorphism in human papillomavirus- associated esophageal cancer Cancer Res 60 2753 2755 1:CAS:528:DC%2BD3cXjvFOls70%3D 10850407
24. M Furihata T Takeuchi M Matsumoto A Kurabayashi Y Ohtsuki N Terao M Kuwahara T Shuin 2002 p53 Mutation arising in Arg 72 allele in the tumorigenesis and development of carcinoma of the urinary tract Clin Cancer Res 8 1192 1198 1:CAS:528:DC%2BD38XksVWjsrw%3D 12006537
25. M Marin C Jost L Brooks M Irwin J Nions J Tidy N James J McGregor C Harwood I Yulug K Vousdrn M Allday B Gusterson S Ikawa P Hinds T Crook W Kaelin 2000 A common polymorphism acts as an intragenic modifier of mutant p53 behaviour Nat Genet 25 47 54 10.1038/75586 1:CAS:528:DC%2BD3cXjtFSltr0%3D 10802655 (Pubitemid 30257035)
26. M Tada K Furuuchi M Kaneda J Matsumoto M Takahashi A Hirai Y Mitsumoto R Iggo T Moriuchi 2001 Inactivating of the remaining p53 allele or the alternate p73? Preferential selection of the Arg polymorphism in cancer with recessive p53 mutant but not transdominant mutants Carcinogenesis 22 515 517 10.1093/carcin/22.3.515 1:CAS:528:DC%2BD3MXitFKhtrc%3D 11238194
27. D Bergamaschi M Gasco L Hiller A Sullivan N Syed G Trigiante I Yulug M Merlano G Numico A Comino M Attard O Reelfs B Gusterson AK Bell V Heath M Tavassoli PJ Farell P Smith X Lu T Crook 2003 p53 Polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis Cancer Cell 3 387 402 10.1016/S1535-6108(03)00079-5 1:CAS:528:DC%2BD3sXjsFGgs74%3D 12726864 (Pubitemid 38340307)
28. A Szymanowska E Jassem R Dziadziuszko A Borg J Limon G Gulida W Rzyman J Jassem 2005 Increased risk of non-small cell lung cancer and frequency of somatic TP53 mutations in pro72 carrier of the arg72pro polymorphism Lung cancer 52 9 14 10.1016/j.lungcan.2005.12.007
29. Y Hu M McDermott S Ahrendt 2005 The codon 72 proline allele is associated with p53 gene mutations in non-small cell ung cancer Clin Cancer Res 11 2502 2509 10.1158/1078-0432.CCR-04-1913 1:CAS:528:DC%2BD2MXivFKju7k%3D 15814626 (Pubitemid 40569446)
30. Y Xu L Yao A Zhao T Ouyang J Li T Wang Z Fan T Fan B Lin Y Lu Y Xie 2008 Effect of codon 72 genotype on breast cancer survival depends on p53 status Int J Cancer 122 2761 2766 10.1002/ijc.23454 1:CAS:528:DC%2BD1cXht1eku7rK 18348141 (Pubitemid 351631378)
31. I Vannini W Zoli A Tesei M Rosetti P Sansone G Storci A Passardi I Massa M Ricci D Gusolfini F Fabbri P Ulivi G Brigliadori D Amodori M Bonafe 2008 Role of p53 codon 72 arginine allele in cell survival in vitro and in the clinical outcome of patients with advanced breast cancer Tumor Biol 29 145 151 10.1159/000143400 1:CAS:528:DC%2BD1cXhtV2isbbL
32. Y Xu L Yao T Ouyang J Li T Wang Z Fan B Lin Y Lu Y Xie 2005 p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer Clin Cancer Res 11 7328 7333 10.1158/1078-0432.CCR- 05-0507 1:CAS:528:DC%2BD2MXhtFartbrN 16243804 (Pubitemid 41507691)
33. S Nordgard G Alnas B Hihn OC Lingjarde K Liestol A Tsalenko T Sorli PE Lonning AL Borresen V Kristensen 2008 Pathway based analysis of SNPs with relevance to 5-FU therapy: relation to intratumoral mRNA expression and survival Int J Cancer 123 577 585 10.1002/ijc.23541 1:CAS:528:DC%2BD1cXotVyhsb0%3D 18498133 (Pubitemid 351898415)